Publications by authors named "Lisa Zieschang"
Article Synopsis
- Acute myeloid leukemia (AML) has a poor prognosis mainly due to the relapse driven by therapy-resistant leukemia progenitor/stem cells (LPCs), leading to the development of peptide-based immunotherapy targeting these cells to improve patient outcomes.
- A therapeutic vaccine called AML-VAC-XS15 was created, consisting of specific peptides from common AML mutations, and is being tested in a phase I clinical trial for its effectiveness and safety in AML patients in remission.
- The study is ethically approved and aims to evaluate the vaccine's ability to generate immune responses and assess its preliminary clinical efficacy while ensuring patient safety through monitoring over two years.
Chronic lymphocytic leukemia (CLL) is the most common form of leukemia among adults in Western countries. Despite the introduction of targeted therapies, including first-line Bruton's tyrosine kinase inhibitor (BTKi) treatment, CLL remains largely incurable. Frequent disease relapses occur due to remaining treatment-resistant CLL cells, calling for novel therapies to eliminate minimal residual disease (MRD).
View Article and Find Full Text PDFArticle Synopsis
- Scientists found a special DNA fusion called DNAJB1-PRKACA that causes a rare liver cancer called fibrolamellar carcinoma (FL-HCC), which mainly affects young people.
- * FL-HCC has a low chance of survival, and surgery is the only way to cure it if it hasn't spread yet; there isn’t a standard medicine for other treatments.
- * A new clinical trial, FusionVAC22_01, is testing a vaccine and an immune booster to help the body fight the cancer by improving the immune system's response against it.
Medicated chewing gums represent an orally administered dosage form with promising potential for local and systemic drug delivery. However, compared to other solid oral dosage forms, formulation development and release mechanism of medicated chewing gums are extremely complex, and thus only few products reached the approval for the market so far. Therefore, Quality by Design (QbD) approaches for rational formulation development of medicated chewing gums are needed to utilize their full potential.
View Article and Find Full Text PDF